Literature DB >> 30953783

Early immunologic changes during the onset of atopic dermatitis.

Patrick M Brunner1.   

Abstract

OBJECTIVE: Atopic dermatitis (AD), which is commonly called eczema, is the most common chronic inflammatory skin disease. The pipeline of new targeted treatments is currently expanding, a development that is largely based on our increasing understanding of disease mechanisms. Mechanistic insights have long been based on long-standing adult AD. Recently, studies also investigated early pediatric AD at disease onset, and revealed several differences in barrier and immune properties when compared with long-standing adult AD. This review focuses on immunological changes very early in life that predispose to the development of AD, and summarizes characteristics of the molecular AD phenotype in this age group. DATA SOURCES: Review of published literature. STUDY SELECTIONS: Studies investigating human AD at disease onset in newborns, toddlers, and young children, in comparison with adults with long-standing disease.
RESULTS: Already in cord blood, increased Th2 and decreased Th1 levels were found to increase the risk of AD development. Both pediatric and adult AD share Th2/Th22 activation and defects in lipid barrier deposition and tight junction formation, but Th1 activation and epidermal differentiation complex defects are largely absent in pediatric AD.
CONCLUSION: Immune changes predisposing to AD development are present very early in life. During the first months of disease, AD shows various differences in immune and barrier properties from long-standing adult AD, which might necessitate tailored treatment approaches depending on the age of the patient.
Copyright © 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30953783     DOI: 10.1016/j.anai.2019.03.033

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  6 in total

Review 1.  Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.

Authors:  Thomas Bieber
Journal:  Nat Rev Drug Discov       Date:  2021-08-20       Impact factor: 84.694

2.  Spontaneously Resolved Atopic Dermatitis Shows Melanocyte and Immune Cell Activation Distinct From Healthy Control Skin.

Authors:  Katharina Rindler; Thomas Krausgruber; Felix M Thaler; Natalia Alkon; Christine Bangert; Harald Kurz; Nikolaus Fortelny; Thomas B Rojahn; Constanze Jonak; Johannes Griss; Christoph Bock; Patrick M Brunner
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

Review 3.  Th1 regulatory events by infectious pathogens, herpes zoster and herpes simplex viruses: prospects for therapeutic options for atopic eczema.

Authors:  Yasuhiro Horiuchi
Journal:  Postepy Dermatol Alergol       Date:  2022-09-01       Impact factor: 1.664

4.  Interferon-γ downregulates tight junction function, which is rescued by interleukin-17A.

Authors:  Yukiko Mizutani; Nao Takagi; Haruna Nagata; Shintaro Inoue
Journal:  Exp Dermatol       Date:  2021-07-10       Impact factor: 4.511

Review 5.  Xenobiotic Receptors and Their Mates in Atopic Dermatitis.

Authors:  Deborah Minzaghi; Petra Pavel; Sandrine Dubrac
Journal:  Int J Mol Sci       Date:  2019-08-29       Impact factor: 5.923

6.  Atopic dermatitis.

Authors:  Elena Galli; Bianca Cinicola; Rossella Carello; Silvia Caimmi; Giulia Brindisi; Giovanna De Castro; Anna Maria Zicari; Maria Angela Tosca; Sara Manti; Alberto Martelli; Mauro Calvani; Claudio Cravidi; Gian Luigi Marseglia; Fabio Cardinale; Michele Miraglia Del Giudice; Carlo Caffarelli; Marzia Duse
Journal:  Acta Biomed       Date:  2020-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.